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Background: Personalized medicine has become a priority in breast cancer patient management. In addition to
the routinely used clinicopathological characteristics, clinicians will have to face an increasing amount of data
derived from tumor molecular profiling. The aims of this study were to develop a new gene selection method
based on a fuzzy logic selection and classification algorithm, and to validate the gene signatures obtained on
breast cancer patient cohorts.
Methods: We analyzed data from four published gene expression datasets for breast carcinomas. We identified the
best discriminating genes by comparing molecular expression profiles between histologic grade 1 and 3 tumors for
each of the training datasets. The most pertinent probes were selected and used to define fuzzy molecular grade
1-like (good prognosis) and fuzzy molecular grade 3-like (poor prognosis) profiles. To evaluate the prognostic
performance of the fuzzy grade signatures in breast cancer tumors, a Kaplan-Meier analysis was conducted to
compare the relapse-free survival deduced from histologic grade and fuzzy molecular grade classification.
Results: We applied the fuzzy logic selection on breast cancer databases and obtained four new gene signatures.
Analysis in the training public sets showed good performance of these gene signatures for grade (sensitivity from 90%
to 95%, specificity 67% to 93%). To validate these gene signatures, we designed probes on custom microarrays and
tested them on 150 invasive breast carcinomas. Good performance was obtained with an error rate of less than 10%.
For one gene signature, among 74 histologic grade 3 and 18 grade 1 tumors, 88 cases (96%) were correctly assigned.
Interestingly histologic grade 2 tumors (n = 58) were split in these two molecular grade categories.
Conclusion: We confirmed the use of fuzzy logic selection as a new tool to identify gene signatures with good
reliability and increased classification power. This method based on artificial intelligence algorithms was successfully
applied to breast cancers molecular grade classification allowing histologic grade 2 classification into grade 1 and
grade 2 like to improve patients prognosis. It opens the way to further development for identification of new
biomarker combinations in other applications such as prediction of treatment response.
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Breast cancer, the most common invasive cancer in women,
is an heterogeneous and complex disease. Currently, the
management of breast cancer patients is based on clinico-
pathological characteristics such as age, menopausal status,
tumor size, lymph node status, histologic grade [1] and on
three immunohistochemical predictive markers: estrogen
(ER) and progesterone (PR) receptors and human epider-
mal growth factor receptor 2 (HER2) [2,3].
Clinicopathological parameters and immunohistochemi-
cal markers are combined in guidelines such as St Gallen’s
consensus and Nottingham [4] prognostic Index or incor-
porated in internet algorithms such as Adjuvant!Online
(https://www.adjuvantonline.com/index.jsp), for treatment
decision making. The combination of these parameters
provides assessments of the benefit of a systemic endo-
crine or chemo-therapy [5]. Although effective in the re-
duction of mortality, these principles have shown limits
and are not sufficient for individualized medicine. Tumors
with similar clinical characteristics can have noticeably
different outcomes in terms of treatment response and
survival. Furthermore, over-treatment with adjuvant ther-
apy is not harmless [6].
For the past decade, genome-wide microarray-based ex-
pression profiling studies have been used as a powerful tool
to improve understanding of the biology of breast cancer
[7-12]. With these technologies, many prognostic gene ex-
pression signatures were identified to predict breast cancer
recurrence risk [13-21]. Molecular differences even among
tumors with similar pathological features have been unrav-
elled and a new molecular taxonomy for breast cancer
classification into several subgroups (luminal A and B,
basal-like, HER2, normal breast-like) has been proposed.
However, most of these gene signatures are still under de-
velopment for prospective validation in clinical trials. Des-
pite the promise of previous gene signatures, decisions
making in clinical practice are still guided by traditional pa-
rameters. Integrating microarray information and using it
as a complement to clinicopathological parameters could
provide more accurate and robust prognostic tests in order
to guide adjuvant systemic treatment that could reduce the
cost of breast cancer treatment.
Biological data obtained from high throughput technolo-
gies (DNA microarray, NGS, and so forth) are known to
generate certain level (amount) of imprecise and noisy data.
Moreover, the high dimensionality of these technologies
data (tens to hundreds of thousands of features) makes use
of machine learning and data mining techniques necessary,
since many of these features are irrelevant or redundant.
Many research efforts have been directed in the last two
decades towards developing efficient feature selection
methods [22-25]. The existing methods are traditionally cat-
egorized as filter or wrapper methods, with respect to the
criterion used to search for relevant features [26,27]. Infilter approaches, features are scored and ranked according
to a certain statistical criteria and those with the highest
ranking values are selected. Most frequently used filter
methods include t-test [28], chi-square [29], Wilcoxon [30],
Pearson correlation coefficients [31] and Principal Compo-
nent Analysis [32]. Filter methods are fast but lack in ro-
bustness against feature interactions and redundancy [33].
Besides, the way to determine the rankings cut-off point to
select only truly important features and exclude noise is not
clear. Wrapper methods use the performance of a learning
method to assess the quality (accuracy) of the selected fea-
ture subset in predicting the target (e.g. determined by cross
validation). Wrapper methods employ search algorithms to
determine an optimal subset of features. The most generally
used search approaches are backward elimination and for-
ward selection [26]. Stochastic algorithms, developed for
solving large scale combinatorial problems, such as ant col-
ony optimization, genetic algorithms, and simulated anneal-
ing are also used [34-36]. Although these algorithms
efficiently capture feature redundancy and interaction they
are computationally expensive. Recently, some authors take
advantage of both filter and wrapper methods and propose
hybrid algorithms [33,37-39]. The idea is to apply first a fil-
ter method to select a feature pool and then the wrapper
method is applied to determine the optimal subset of fea-
tures from the selected pool. The most popular learning al-
gorithm used in wrapper methods is the support vector
machines (SVM) [40]. Nevertheless, the accuracy of an
SVM depends on the choice of the parameters and the ker-
nel function. SVMs are sensitive to noisy training data,
which can degrade their performance. Even more, they are
prone to over-fitting and poor generalization. The principal
drawback of wrapper methods is the computational cost,
since they evaluate the feature subset with a learning algo-
rithm, which are usually iteratively. Therefore to enhance
the wrapper approach performance it is necessary to use
fast learning algorithms which performs well when dealing
with noisy and imprecise data.
Fuzzy logic was introduced in 1965 by Zadeh [41], it
deals with reasoning that is approximate rather than fixed
and exact. Contrary to traditional Boolean logic, where ob-
jects are classified either true (1) or false (0), in fuzzy logic,
they may have values ranking from 0 to 1. Fuzzy logic has
been widely used in system control due to its simplicity and
effectiveness, especially in the case of nonlinear and high-
dimensional systems. This is mainly due to its fundamental
concept which enables to handle and manipulate imprecise
and noisy data. Additionally, it provides an intuitive inter-
pretation of the results. Although some attempts to use
fuzzy logic to perform feature selection have been pro-
posed [42-49], certainly these methods perform well
when dealing with imprecise and noisy data but they gen-
erally end up with a high sophistication. Either they de-
pend on a specified method (e.g. Fuzzy C-Means [50])
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arbitrary choice to determine the linguistic terms of the
“fuzzified” features, which is not always possible and
accurate enough whenever a big number of features
must be tackled. Moreover, in order to reduce compu-
tational cost, some authors have combined fuzzy selec-
tion mechanisms with genetic algorithms or even have
introduced the concept of fuzzy entropy for selecting
relevant features [44-46].
Fuzzy classifiers have recently shown their effectiveness
in classification tasks, since they enable dealing with noisy
and imprecise information which is often present in many
applications. However, their performances decrease signifi-
cantly in case of high dimensional and/or heterogeneous
problems. Despite these drawbacks, an increasing interest
in applying fuzzy classifiers to breast cancer prognosis,
using gene expression data has been observed [51,52].
In contrast to previous studies where fuzzy logic was
used for assessing patient classification, we herein devel-
oped feature selection and classification algorithms both
based on the fuzzy logic concept of membership degree.
Our approach involves feature weighting based on a mem-
bership margin in order to improve the performance of
fuzzy classifiers on high dimensional and heterogeneous
problems. The effectiveness of this method has been pre-
viously demonstrated on problems involving mixed type
of data (numerical, qualitative, symbolic intervals) [53].
One of the most important parameter in breast can-
cer is the histological tumor grade which classifies pa-
tients in three classes: 1, 2 or 3. Histologic grade 1 and
3 statuses are related to a low and high risk of recur-
rence, respectively. However, about 50% of tumors are
classified as histologic grade 2, the moderately differen-
tiated grade [13,14]. This grade is associated with an
unclear risk of recurrence and is thus not informative
for clinical decision making. Individualized medicine,
not only based on clinicopathological characteristics,
but also using information derived from tumor molecu-
lar profiles could improve patient management and in-
crease survival. However it remains a clinical challenge.
We have applied this new fuzzy logic methodology on
gene expression data information obtained from public
available datasets and our own patients cohort. We iden-
tified gene signatures enabling accurate discrimination of
patients with breast cancer into either grade 1 or grade 3
and to help classifying patients with histologic grade 2 tu-
mors into grade 1 or grade 3 like. This classification could
lead to a reduction of over- and under- treated patients.
Results
Gene signatures according to fuzzy molecular grade (fMG)
We applied the fuzzy logic selection algorithm MEM-
BAS on four public available cohorts to identify prog-
nostic gene expression signatures for breast cancer,based on histologic grade. The use of several cohorts
allowed taking into account a maximum heterogeneity
of patients. Due to the different microarray platforms
(Affymetrix, Agilent Technologies), experimental pro-
tocols and data processing for normalization used by
authors, we choose to use gene expression raw data
individually. In the training sets, we analyzed expres-
sion profiles of 452 patients with primary breast can-
cer with histologic grade 1 or 3. Histologic grade 2
patients were excluded since our objective was to
identify low and high risk profiles in order to classify
later intermediate grade tumors as molecular grade 1-
like (fMG1) or 3-like (fMG3). Tumor data were de-
rived from four independent cohorts: NKI2-Agilent
(113 samples) [16], KJX64KJ125-GSE2990 (103) [14],
Uppsala-GSE4922 (123) [13], and Transbig-GSE7390
(113) [6]. The training sets were used to identify groups of
genes whose expression allowed distinguishing histologic
grade 1 from grade 3 tumors. MEMBAS algorithm ranked
in decreasing order the probes and a posterior probability
was iteratively estimated for each tumor by leave-one-out
cross validation (LOOCV). We performed selection of
the minimal number of probes which achieved the
highest possible sensitivity (Histologic Grade HG3 pa-
tients correctly identified) and an acceptable level of
specificity (HG1 patients correctly classified), in order
to have accurate grade assignments (Figure 1). In breast
cancer context, a high sensitivity is privileged over high
specificity in order to be sure that patients with high
risk of recurrence would be thoroughly treated.
We identified 67 Agilent probes and 38 Affymetrix
probes respectively for the gene signatures A and B, de-
signed from only ER positive patients of NKI2 and
KJX64-KJ125 cohorts; whereas gene signatures C and D
were composed of respectively, 71 and 18 Affymetrix
probes selected on both ER positive and negative tumors
for Uppsala and Transbig cohorts. These probe sets cor-
respond respectively to 65, 37, 65 and 16 unique genes
respectively. Most genes were overexpressed in grade 3
tumors. As highlighted by molecular taxonomy, ER posi-
tive and ER negative breast cancers are fundamentally
different diseases and ER status may influence gene ex-
pressions. For this reason, we tested ahead stratification
of tumors, according to their ER status (either only ER
positive or both ER positive and negative) and selected
the gene signatures with the best discriminant power for
each cohort, regardless of ER status for patients included
in the training set.
When we compared the new gene signatures obtained
with our fuzzy logic strategy with the previously pub-
lished prognostic signatures, we found several genes in
common (Additional file 1: Table S1). For example in
gene signature C [13], 14 of the 18 genes from the PAM
genetic grade signature [13] were identified. More than
Figure 1 Selection of the most discriminant probes for GS C – GSE4922 [13]. Minimum number of probes providing the best sensitivity with a
low global error. A) Global Error, B) Sensitivity, C) Specificity. The number of evaluated probes is expressed in a log 10 scale (horizontal axis).
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B [14], C [13] and D [6] were common to Sotiriou’s GGI
signature [14].Grade 1&3 profiles - training set
We examined the performance of our gene signatures in
predicting histologic grade 1 and 3 by determining whether
Figure 2 Membership degree of a patient X to both molecular
grade 1(green) and grade 3 (red) classes. The gray rectangle, for
membership values around 0.5, corresponds to an uncertainty zone
where gene expression values are intermediate.
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agrees with the histologic ones. Sensitivity and specifi-
city rates of each signature on the respective training
sets are summarized in Table 1. Best results were obtained
with gene signature C on Uppsala cohort [13]. Only 3 out
of 55 histologic grade 3 tumors (5%) were classified in mo-
lecular grade 1-like and 5 out of 68 histologic grade 1 tu-
mors (7%) were assigned to molecular grade 3-like.
Secondly, gene signatures A [16] and B [14] achieved a
sensitivity of 90% (5/49 and 4/40 misclassifications of
grade 3) and a specificity of 86% and 87% respectively
(9/64 and 8/63 misclassifications of grade 1). Gene sig-
nature D [6] presented a high rate of sensitivity (93%)
and a lower specificity (67%), likely due to an imbalance
in the composition of grade 1 and 3 tumors in this co-
hort and to a lower number of grade 1 tumors. To sum
up, cancer grades prediction obtained from the four
signatures strongly correlated with those obtained from
histologic data.
As detailed in the Methods section (Figure 2), to quan-
tify the degree of membership to molecular grade 1-like
(fMG1) and 3-like (fMG3), a molecular grade score was
developed. As shown in Figure 2, a tumor displaying a
grade 3-like gene expression profile is assigned with a
score (membership degree) greater than or equal to 0.5,
whereas a score below 0.5 corresponded to a tumor dis-
playing a grade 1-like gene expression profile. The values
of molecular grade score for all datasets are shown in
Figure 2.
Molecular grade scores were well correlated to the
gene expression patterns in Figure 3. The four gene sig-
natures with molecular grade scores accurately classified
grade 1 and 3 tumors with few misclassifications.
Grade 2 classification - training set
To determine if we were able to separate histologic grade
2 tumors in two classes, i.e. grade 1-like and grade 3-like,









fGS A NKI2 [16] 206 G1
G3
fGS B KJX64-KJ125 [14] 166 G1
G3
fGS C Uppsala [13] 249 G1
G3
fGS D TVBDX [6] 196 G1
G3
% in bold correspond to specificity (HG1) and sensibility (HG3).preserving the same profiles of histologic grade 1 and 3
tumors (Table 1). The gene expression profiles of the
histologic grade 2 tumors were similar to either molecular
grade 1 profile or molecular grade 3 profile (Figure 3).
Thus Figure 3 shows that most grade 2 tumors can be
molecularly separated either into grade 1-like or grade 3-
like classes.
Although our fuzzy gene signatures could accurately
distinguished grade 1 from grade 3 tumors and sepa-
rated grade 2 tumors in grade 1 like or grade 3 like, we
defined an indecision zone that scored arbitrarily be-
tween 48 and 52%, due to the equivocal gene expression
grade profile of these patients (Figure 3 Heat map). For
patients whose classification score lies within this uncer-
tainty zone, their gene expression grade profile cannot
be determined with certainty. Equivocal profiles repre-
sented a sizeable part of tumors (20 to 41%) according
to the cohort, and this is particularly highlighted by
the slope of the grade 2 molecular score on the fGS C
(Figure 3, fGS C bottom panel). The origins of these
intermediate tumors are unclear and could be bio-




n % n % n %
55 (86) 5 (10) 46 (49)
9 (14) 44 (90) 47 (51)
55 (87) 4 (10) 38 (60)
8 (13) 36 (90) 25 (40)
63 (93) 3 (5) 82 (65)
5 (7) 52 (95) 44 (35)
20 (67) 6 (7) 32 (39)
10 (33) 77 (93) 51 (61)
Figure 3 Heat maps for fGS A, B, C and D in their corresponding training sets [16,14,13,6]. Each dataset was standardized along rows so
that the mean is 0 and the standard deviation is 1. Red corresponds to positive expression values and green to negative expression values. Color
intensity reflects the magnitude of expression relative to the mean. Rows correspond to gene probe sets, ranked in descending order (from bottom to
top) according to MEMBAS feature selection algorithm. Columns of heat maps correspond to tumors, which were grouped according to their assigned
molecular profile (LAMDA classification). TOP panel: Red dots = molecular grade 3 profile; green dots = molecular grade 1 profile. Vertical axis
corresponds to tumors’ histologic grade (HG3, HG2 and HG1 from bottom to top). BOTTOM panel: Molecular Grade score of each tumor is
plotted below the corresponding column.
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independent validation sets
An important aspect of our fuzzy gene signatures (fGS)
is their performance. It has to be assessed on cohortsfrom various origins, including a validation set. There-
fore, we tested the four fuzzy gene signatures (fGS) on
several independent patient cohorts. We used exactly
the same probes than the ones included in each fGS in
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gene signature A could not be validated on an independ-
ent dataset due to the deficiency of other Agilent plat-
form datasets. Furthermore, redundant patients present
in KJX64/KJ125 and Uppsala datasets were removed
from the validation tests so they were only considered
once. Validation tests showed that gene signatures B, CFigure 4 Cross validation of fGS B. Genes of the fGS B were mapped
A) Uppsala (GSE4922) [13]; B) Transbig (GSE7390) [6]; and C) Stockho
used to calculate molecular grade profiles; HG2 tumors were classified as fM
molecular grade score (bottom panel).and D achieved similar performances to those obtained
in training sets with about 80-90% of sensitivity (classi-
fication of HG3 tumors) and specificity (classification
of HG1 tumors), and error rates between 7 to 17%
(Additional file 2: Table S2). Figure 4 shows the cross val-
idation fGS B on the different cohorts. We observed a
suitable agreement in classification between molecularto three previously published breast cancer microarray datasets:
lm (GSE1456) [13]. HG1 and HG3 tumors from each dataset were
G 1-like or fMG 3-like (top panel) and sorted according to their
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histologic grade 1 and 3 tumors for each gene signature
were similar to those identified in the training set (Figure 3
fGS B). We also found, as in the training set, close associa-
tions between the gene expression profiles, fuzzy molecu-
lar grade scores and histologic grades. We can notice that
it exhibited good results with both ER positive and nega-
tive tumors although its fuzzy molecular grade score was
constructed initially with only ER positive tumors to avoid
bias. Furthermore, we calculated fuzzy molecular grade
scores for grade 2 tumors in validation sets. We observed
that, albeit an equivocal zone was observed, most grade 2
tumors could be separated in fMG 1-like and fMG 3-like
(Figure 4).
Correlation between fuzzy molecular grade score and
relapse-free survival
To estimate the prognostic performance of gene signa-
tures in breast cancer patients, the Kaplan-Meier
method [54] was used to compare the relapse-free sur-
vival deduced from histologic classification to that
from fuzzy molecular classification.
The reliability of molecular grades in the different
datasets and in pooled datasets was tested. Histologic
grade 3 tumors were associated with a high rate of re-
lapse whereas histologic grade 1 tumors were related to
a low risk of recurrence. Histologic grade 2 tumors wereTable 2 Survival analysis of grade 1 and 3 tumors classified w
fuzzy Gene
Signature
HG 1&3 patients fuzzy Gene Signatures
n Hazard Ratio (95% CI) p
fMG A
NKI2 training 113 2.136 (1.466 - 3.113) <
NKI2 validation all 163 1.989 (1.463 - 2.704) <
fMG B
KJX64/KJ125 training 99 1.923 (1.342 - 2.754) <
Transbig 113 1.435 (1.005 - 2.051) <
Stockholm 89 2.711 (1.313 - 5.595) <
Pool 1 272 1.59 (1.25 to 2,02) <
fMG C
Uppsala training 123 1.484 (1.091 - 2.017) <
Stockholm 89 4.134 (1.518 - 11.258) <
fMG D
Transbig Training 113 1.28 (0.852 - 1.923) =
KJX64/KJ125 122 1.591 (1.157 - 2.186) <
Stockholm 89 3.844 (1.412 - 10.469) <
Pool 2 281 1.65 (1.31 to 2,07) supp KJX <
Pool 1: Uppsala + Transbig + Stockholm.
Pool 2: KJX64/KJ125 + Uppsala + Stockholm.associated with an intermediate rate of relapse. We per-
formed the same survival analysis with fuzzy molecular
grade obtained with the four gene signatures. The results
summarized by hazard ratios, 95% confidence intervals
and p value, are presented in Table 2. The hazard ratio
from all datasets classified with the four gene signatures
showed significant log rank test p value. Only gene sig-
nature D failed to reach significance in its training set
(Transbig cohort), however histologic grading did too.
As shown in Table 2, discriminating grade 1 from grade
3 tumors with our Fuzzy molecular method exhibited
better results than with the histologic one. In addition,
while survival curves of molecular grade 1 and 3 were
similar to those of histologic grade 1 and 3 respectively,
in some cases, fuzzy gene signatures could be better
than the histologic grade classification in improving re-
lapse free survival for patients with grade 1 and 3 tu-
mors (Additional file 3: Figure S1).
To evaluate the clinical interest of molecular grades,
grade 1-like and grade 3-like, we compared the relapse-
free survival of grade 2 patients who had grade 1-like
profile with that of patients who had grade 3-like pro-
file, according to the four gene signatures. The four
fuzzy molecular grade signatures separated grade 2 tu-
mors into 2 distinguished classes, grade 1-like and
grade 3-like, with a statistically significant difference in
relapse-free survival across all datasets or whenith fuzzy molecular and histologic grades
Histologic grade
value logrank test Hazard Ratio (95% CI) p value logrank test
.001 1.5896 (1.135 - 2.213) <0.0052
.001 1.694 (1.294 - 2.218) <.001
.001 1.546 (1.075 - 2.223) <0.0184
0.0426 1.062 (0.792 - 1.426) =0.0541
0.00158 2.104 (1.28 - 3.459) <0.0103
0.0001 1.55 (1.20 to 2.00) <0.001
0.0103 1.773 (1.306 - 2.408) <.001
.001 2.104 (1.28 - 3.459) <0.0103
0.23 1.062 (0.792 - 1.426) =0.0541
0.00312 1.518 (1.11 - 2.077) <0.00725
.001 2.104 (1.28 - 3.459) <0.0103
0.00001 1.66 (1.32 to 2.09) <0.00001
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S3). Grade 2 tumors with grade 1-like profile had a lower
risk of recurrence than grade 3-like.
We examined several variables in a univariate ana-
lysis (Additional file 5: Table S4) and found that gene
expression grade of our fGS, histologic grade, lymph-
oma node status and tumor size were all statistically
significantly associated with relapse-free survival.
However, in a multivariable analysis, only our fuzzy
Gene Signature (fGS) and tumor size remained statisti-
cally significant associated with relapse-free survival.Figure 5 Relapse free survival analysis of patients with histologic gra
(red) by fuzzy Gene Signatures (fGS). Hazard ratios with 95% confidence
significance (fMG1-like vs. fMG3-like). (A) For fGS A, NKI2 cohort was used (
conducted with pooled data of KJX64/KJ125, Uppsala, Stockholm, Transbig
pooled (n = 184).Our fGS having the strongest association: HR = 1.51,
95% CI = 1.21 to 1.88; P < 0.0004 .
Fuzzy molecular grade (fMG) validation on an
independent cohort
ICR cohort on Nimblegen custom microarray
In order to evaluate the performance of our four gene
signatures, we designed a NimbleGen custom microarray
with the genes obtained on our gene signatures and
validated them thanks to expression profiles of breast
cancer tumors from a new cohort (C. Regaud Institute,de 2 tumors (black) classified in fMG1-like (green) and fMG3-like
intervals (CI) and log-rank test (p value) were calculated to evaluate
n = 93). (B, D) For fGS B and D respectively, Kaplan-Meier analysis were
cohorts (n = 309). (C) For fGS C, Uppsala and Stockholm cohorts were
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tumors (11.9%), 58 (38.7%) grade 2 and 74 (49.3%)
grade 3 tumors. The custom NimbleGen array was
composed of genes of interest with 9 probes for each
transcript. We used MEMBAS selection algorithm, in-
stead of the conventional mean value, in order to rank
(descending order) all probes representing the genes
included in a gene signature. We selected the bestFigure 6 Heat maps for fuzzy gene signatures A, B, C and D in the va
to calculate molecular grade profiles; HG2 tumors were classified as f
fuzzy molecular grade 3 score (bottom panel).ranked probe for each gene (Additional file 5: Table S4).
Fuzzy molecular grade 1 and 3 profiles were determined
with these selections and with LAMDA classification
algorithm.
Grade 1 & 3 profiles
With Nimblegen microarrays constructed with the newly
designed probes based on our fuzzy gene selection aslidation set (ICR): for each fGS, HG1 and HG3 tumors were used
MG 1-like or fMG 3-like (top panel) and sorted according to their
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pression profiles on ICRs cohorts for consistency with
predicted histologic grade. As shown in Figure 6, the
gene expression patterns of patients with histologic
grade 1 (n = 18) and grade 3 (n = 74) tumors were simi-
lar to those identified previously in the training and val-
idation sets from public datasets.
A total of 125 probe sets (representing 122 genes)
were identified as genes with the highest discriminating
power (i.e. the most significantly differentially expressed
genes) between grade 1 and grade 3 tumors.
For all fuzzy gene signatures, we could easily discrim-
inate low and high grade from the gene expression pat-
terns of the ICR cohort. The accuracy of fuzzy molecular
grading in terms of classified in low and high grade (fMG1
and fMG3) was evaluated using a LOOCV, since the num-
ber of grade 1 tumors is very small (11.9%) compared to
the number of grade 3 tumors (49.3%). Results for high
sensitivity and specificity are shown in Additional file 6:
Table S5. For example, using fGS B, only one of the 18
HG 1 tumors (6%) showed a fuzzy molecular grade
score greater than 0.5, and only three of the 74 HG 3
tumors (4%) displayed a fuzzy molecular grade score in-
ferior to 0.5.
Most importantly, we noticed that misclassifications
between gene signatures often corresponded to the same
tumors. Indeed, in all four gene signatures, four tumors
consistently showed an opposite molecular grade as
compared to their histologic grade. Other tumor mis-
classifications were obtained in two or only one gene
signature. Several of these tumors presented clinicopath-
ological features that could explain these problems of
concordance. Among the misclassified histologic grade 3
tumors, two tumors were invasive lobular carcinoma, of
pleomorphic subtype (cases #37 and 113). One tumor
corresponded to a heterogeneous tumor (as of micropa-
pillary and IDC-NST histologic subtypes) (case #109).
Another tumor displayed a triple negative phenotype
(case #127). Two misclassified histologic grade 1 tumors
were heterogeneous tumors with distinct components
(cases #6 and 96), easily identified by microscopic exam-
ination (one case harboring a mucinous component, the
one measuring 23mm of greater size).
Grade 2 classification in fMG1-like or fMG3-like categories
After checking the accuracy of the fuzzy prediction model
on grade 1 and 3 tumors with the new design of probes, we
tested the profiles of histologic grade 2 tumors (n = 58). As
for the public datasets, the histologic grade 2 tumors har-
bored extreme values than encompassed those of histologic
grade 1 and 3 tumors (Figure 6). It could be noticed that
69% of grade 2 tumors were classified identically by the
four gene signatures. Only 7% (4/58 tumors) of grade 2 tu-
mors were ambiguously classified as fMG1-like by two genesignatures and as fMG3-like by the two others. Among
these 4 tumors, 3 were within the equivocal zone. This
demonstrates that the use of several gene signatures may
prove useful to enhance confidence on prognostic informa-
tion provided by molecular grade.
Discussion
It has been shown that breast cancer histologic grade
provides an important prognosis information, with grade
1 tumors showing a low risk of recurrence as opposed to
grade 3 tumors harboring a high risk of recurrence.
However, about 50% of breast cancers are classified as
moderately differentiated (intermediate) histologic grade
2, which gives no information about the clinical decision
or the treatment strategy to apply. Microarray gene ex-
pression data has been employed in order to increase
the prognostic value of tumor grading, on the one hand
by refining grade 2 tumors into two distinct categories
which could be eventually related to low and high risk,
and on the other hand improving reproducibility. In
contrast to what has already been done, we have herein
used a feature selection algorithm and a classifier based
on fuzzy logic theory and concepts, in order to identify
genes that best discriminate grade 1 from grade 3 tu-
mors. We applied this approach to four previously pub-
lished microarray datasets (Agilent and Affymetrix
technologies) and generated four distinct fuzzy gene sig-
natures. We found that all four grade signatures were
able to reliably identify histologic grade 1 and 3 tumors
and molecularly separate grade 2 tumors into fMG1-like
or fMG3-like categories, regardless of the platform tech-
nology, experimental protocols or type of cohorts. The
fact of applying the membership concept (i.e. a sample
belongs simultaneously to each category with a given
value of confidence) allowed representing the heterogen-
eity of tumors without the necessity of preprocessing
into molecular subtypes. Hence, only those probes that
truly contributed to the characterization of both grade 1
and grade 3 categories were selected. Moreover, the pro-
posed fuzzy gene signatures succeeded to extend good
classification results in other populations. The results
were reproducible and gene signatures were validated
across cohorts.
Identified genes from Fuzzy GSs
As expected, the majority of genes selected with fuzzy
logic encompassed genes involved in cell cycle control
and proliferation. Only one gene, CENPA, was common
to all four GS. The centromere protein A (CENP-A) is
an essential centromere protein, required for chromo-
some segregation during cell division. CENP-A has been
associated with high grade cancers and is a strong
prognostic marker for distant relapse in ER-positive
breast cancer. McGovern SL and their collaborators
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gree of expression of this essential protein and outcome
in ER-positive breast cancer. Seven genes – AURKA,
CDCA8, DDX39A, FOXM1, KIF2C, MELK, MKI67-
were common to GS B, C and D (Affymetrix technol-
ogy) (see Additional file 7: Table S6 and Venn Diagram
Additional file 8: Figure S2). From the 122 selected
genes, 46 of them are unique to GS A (Agilent), and 10,
23 and 1 are unique to GS B, C and D respectively. For
GS A and B, generated with ER positive samples only, 7
genes overlapped (CENPA, BIRC5, CCNB1, KIF20A,
KPNA2, RACGAP1).
Comparison of our four GS (122 selected genes) with
previously published genetic grade signatures revealed a
significant degree of overlap, in particular with PAM
(Ivshina et al.) and GGI (Sotiriou et al.), where for
some GS more than 77% of the genes overlapped.
These findings not only confirm the good performance
of our approach (in terms of biological coherence) but
also reinforce the fact that gene expression-based pro-
files of histologic grade can contribute to patient prog-
nosis identification.
Equivocal cases
Although gene signatures accurately classify grade 1 and 3
tumors and separate grade 2 tumors in grade 1-like or
grade 3-like, we noticed an uncertainty zone where mo-
lecular profiles were intermediate. This uncertainty zone
(see Methods Figure 2) was confirmed by the molecular
grade score value. In fact, for tumors displaying a score
around 0.5, their molecular profile did not show a clear
similarity neither to grade 3 nor to grade 1 profiles. Whilst
it has been recently advocated, no consensual definition of
this uncertainty zone is currently available in the litera-
ture. Arbitrarily, we defined as equivocal those cases with
a classification score between 0.48 and 0.52. For patients
whose classification score lies within this uncertainty zone,
their gene expression grade profile cannot be distinctly de-
termined as grade 1-like or grade 3-like.
When cross validation of our fuzzy gene signatures
was performed on public cohorts, equivocal profiles (all
histologic grades included) represented a more or less
significant part of tumors, ranging from 12 to 31.3% de-
pending on the cohort. Albeit the origins of these inter-
mediate tumors remain unclear and debatable, it most
likely corresponds to a true biological process, reflecting
the spectrum and continuum of disease found in ER+
breast cancer, especially with regards to proliferation.
Some of these equivocal cases could also represent het-
erogeneous tumors with a mixture of grade 1 cells and
grade 3 cells.
Likewise, concerning the results obtained when apply-
ing our gene signatures to the ICR cohort we noted that
gene signatures could disagree for some tumors in theassignment of histologic grade 2 into grade 1-like or
grade 3-like. Thus, we investigated whether problem-
atic histologic grade 2 tumors had extreme or inter-
mediate profiles. We analyzed the range of scores of
grade 2 tumors and we observed a continuous score
slope as for grade 1 and 3 tumors. Furthermore, we
noticed that gene signatures produced about 9% of
equivocal profiles (between 7 to 11% of the cases de-
pending on the gene signature). Whatever the grade
gene signature, an intermediate zone thus exists. Most
of grade 2 tumors classified differently by several gene
signatures also corresponded to equivocal cases (their
classification score ranging between 0.48 and 0.52).
Conclusion
In conclusion, our approach of fuzzy genetic molecular
grading allows refinement of histologic grade 2 tumors
into fMG1-like and fMG3-like categories, although an un-
certainty zone still remains. This suggests that genetic
grade could be used, at some degree and at the very best
in combination to clinicopathological parameters, to fur-
ther improve outcome prediction of patients that should
be spared of systemic adjuvant therapy. It seems that one
unique Gene Signature might not be sufficient enough for
decision making. Several gene signatures might thus be
used to enhance confidence on prognosis provided by mo-
lecular grade. Moreover, the use of both clinicopathologi-
cal characteristics and information derived from tumor
molecular profiles could improve patient management
and increase survival. It is noteworthy that our fuzzy fea-
ture selection algorithm and classifier is capable of treat-
ing features of different types simultaneously. The next
challenge will be to include relevant clinicopathological
characteristics into our fuzzy molecular grade signatures.
Future works will be therefore oriented in evaluating our
fGS performance in association to other parameters, in in-
dependent and larger cohorts.
Finally, we have demonstrated here the proof of con-
cept of using fuzzy logic to select relevant biomarkers
and to better evaluate risk. Individualized medicine re-
mains a clinical challenge and will still need new prognos-
tic and predictive biomarkers. The fuzzy logic method
might prove of useful value in discovering new biomarker
combinations in other main applications such as predic-
tion of treatment response.
Methods
Breast microarray datasets
We collected four public available datasets from pa-
tients with primary breast cancer profiled using Affy-
metrix or Agilent DNA microarrays: the Netherlands
Cancer Institute NKI2 dataset from van de Vijver et al.
(256 patients), the KJX64/KJ125 datasets from Sotiriou
et al. (189 patients), Uppsala dataset from Ivshina et al.
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dataset from Desmedt et al. (198 patients). Some sam-
ples of the NKI2 cohorts were excluded from our study
due to missing or biased data. Redundant patients (74
samples) present in KJX64/KJ125 and Uppsala datasets
were removed from the validation tests so they were
only considered once. Gene expression and clinical data
of public series were retrieved from Gene Expression
Omnibus (GEO) public database http://www.ncbi.nlm.nih.
gov/geo, author’s website and publications [6,13,14,16].
All datasets were retrospective. They are described in
Additional file 9: Table S7.
Selection of grade gene signatures and class prediction
To evaluate cancer recurrence risk, we identified gene
signatures using information on the histologic grade.
The aim was to classify grade 2 tumors with unknown
outcome, into two subclasses: a grade 1-like subgroup
with good outcome and a grade 3-like subgroup with
poor outcome. For this, a feature selection technique
and a classification algorithm based on fuzzy logic con-
cepts were used.
Fuzzy feature partition
Fuzzy set theory was proposed by Zadeh in 1965 to math-
ematically model the imprecision inherent to some con-
cepts [41]. In short, fuzzy sets theory allows an object to
partially (simultaneously) belong to a set (class) with a cer-
tain degree of membership between 0 and 1. In a machine
learning framework, an approach is defined as “fuzzy” if
we consider that an individual belongs to each class with a
certain degree of membership, unlike the “crisp” (“hard”)
approaches where each individual is considered to belong
only to one class [56]. Taking this in consideration, we can
apply these concepts to the problem of classifying breast
cancer patients according to their fuzzy molecular (gene
expression) grade (fMG) profile corresponding to a grade
1-like profile (fMG1) and a grade 3-like profile (fMG3).
Figure 2 shows a representation of the membership de-
grees associated to each class for a group of patients.
Then, patient X, in the figure, has a membership degree of
0.8 for fMG1 and 0.2 for fMG3. An ambiguous (or uncer-
tainty) zone can be defined around a membership degree
value of 0.5, representing those patients for which a low
or high risk profile cannot be clearly associated, i.e. their
molecular grade profile is really intermediate (see “gray
rectangle” on Figure 2).
Grade-associated gene selection
Fuzzifying gene expression data
In order to represent all the features (gene expression
values) of a sample (patient/tumor) by their memberships
to a reference fuzzy partition (molecular grade 1-like & 3-
like), we used membership functions denoted as μk
i basedon the similarity (or distance) semantics [57]. As stated
by Medasani and Kim [58], no measures are available to
evaluate the goodness or correctness of a given member-
ship function, nevertheless the success of an algorithm de-
pends on the membership functions used. Several
functions should be used in order to select the one that
gives the best performance for pattern recognition accord-
ing to the type of data (see Additional file 10). In this
work, the fuzzy extension of the binomial function and
the Gaussian function were used [58]. The first one, works
extremely well when the observations are grouped, after
standardization (see eq.1), around 0 or 1, but may present
instability or definition problems when data is concen-
trated around 0.5. The second one is commonly used
when the volume of the observed data is important, since
it is very likely to follow a Gaussian or semi-Gaussian dis-
tribution. Also, this function measures the proximity to an
estimated center. In this way gene expression values are
transformed into the membership space without any in-
formation loss and are ready to be used for both feature
selection and classification.
Fuzzy feature selection algorithm - MEMBAS
As previously mentioned existing feature selection algo-
rithms are traditionally characterized as wrappers or filters
according to the criterion used to search the relevant
features [27,28]. We have recently proposed a new fea-
ture selection algorithm, referred to as MEMBAS for
MEmbership Margin Based Attribute Selection [59]
which enables to process similarly the three data types
(numerical, qualitative, interval) based on an appropri-
ate mapping using fuzzy logic concepts. The algorithm
measures simultaneously the contribution of each gene
for each of the two classes (in our case, Molecular
Grade1 & Grade3 tumors), in order to find the best dis-
crimination. That is, it extracts the most pertinent
markers since it is based on feature weighting accord-
ing to the maximization of a membership margin. To
avoid the heuristic search during the feature selection
procedure, MEMBAS optimizes a membership margin
based objective function by using classical optimization
techniques providing an analytical solution [60].
Class prediction - Fuzzy classification algorithm
The learning and classification algorithm, LAMDA (Learn-
ing Algorithm for Multivariable Data Analysis) [61] has
been used to generate the fuzzy partition that best discrimi-
nates histologic grade 1 and 3 patients according to their
gene expression profiles, as well as to determine the probes
that best fit this partition. LAMDA is a fuzzy methodology
of conceptual clustering and classification which is based
on finding the global membership degree of a sample to an
existing class, considering all the contributions of each fea-
ture. This contribution is called the marginal adequacy
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membership function and they are then combined using
“fuzzy mixed connectives” as aggregation operators in order
to obtain the global adequacy degree (GAD) of an element
to a class. Finally a sample (tumor/patient) will be
assigned to the class for which its GAD is the highest
[62]. In Hedjazi et al. [60] and his PhD manuscript [63]
an extensive experimental study, including a compari-
son with known feature selection methods has been
performed on several datasets presenting mixed-type
and high-dimensional data. The experimental results in
these works show that MEMBAS leads to a significant
improvement of classification performance of LAMDA
(fuzzy classifier) as well as other well-known classifiers
(k-NN, SVM). Moreover, the combined fuzzy model
MEMBAS/LAMDA works well in datasets with mixed-
type data, since the same fuzzifying process (member-
ship functions) is used for both feature selection and
classification. This provides a similar processing for
each feature type with minimal loss of information.
Fuzzy molecular grade – gene signature strategy
For each breast cancer cohort we identified the most rele-
vant genes using MEMBAS/LAMDA algorithms. The
procedure was as follows:
1. The cohort database was separated into a training
set (histologic grade 1 and grade 3 patients) and a
validation set (histologic grade 2 and unknown grade
patients). Gene expression values were then
standardized within the interval [x_imin, x_imax].
This linear re-scaling of the variable into the interval
[0,1] was performed according to equation (1) where
x̂i is the i-th gene probe (feature) and xi is its nor-
malized value; x_imin and x_imax are the bounds of





This standardization, based only on histologic grade
1 and grade 3 status, was necessary since gene
expression values in different platforms are scaled by
unknown parameters and because grade
compositions diverge between datasets.
2. Next, each gene probe value was fuzzified using the
training data based on the appropriate learning
process (LAMDA). The resulting fuzzy sets represent
the probe’s (feature) membership to each of the two
existing classes. Probe fuzzification was performed
according to two membership functions proposed by
Aguado and Aguilar in [64]. Both functions were
tested in order to identify which gene subsets
provided the highest discrimination power (theobjective is to find the highest classification accuracy
with a minimum number of probes).
3. Once all gene expression values from probes had been
fuzzified, the fuzzy feature selection algorithm
MEMBAS was performed to rank probes in
descending order according to their resulting fuzzy
weight (wf). Then, iteratively, the classification
performance in terms of overall classification error,
sensitivity (percentage of histologic grade 3 tumors
correctly classified), and specificity (percentage of
histologic grade 1 tumors correctly classified) was
calculated using LAMDA classification algorithm.
Hence, for each iteration, the number of probes was
incremented, following the ranked order, until the
whole probe set was tested. Since most cohort
datasets are scarce and small (in terms of patient
number), classification performance was evaluated
with a leave-one-out cross-validation (LOOCV) to es-
timate the optimal classification parameters as pro-
posed by Wessels et al. [65]. This method consists in
holding out one single sample from the histologic
grade 1 and grade 3 dataset of the cohort. This sample
was considered as the validation data and the
remaining histologic grade 1 and grade 3 samples of
the cohort were used to estimate the optimal parame-
ters of the classifier (profile of each class, exigency-α).
The resulting model was employed to classify the test
sample. This was carried out on all samples so that
each of them was used once for testing. This proced-
ure is commonly used to evaluate the generalization
performance of a classifier, since it reduces bias from
the training set, i.e. data for a sample (tumor) are
never used to estimate the classifier parameters (class
profile) for its own classification. The resulting probe
set, providing the higher classification performance,
characterizes the fuzzy Molecular Grade 3-like
(fMG3) and fuzzy Molecular Grade 1-like classes.
4. Given that LAMDA classification provides a global
adequacy degree (GAD) for each sample to both
classes (Figure 2), a molecular grade score has been
introduced in order to determine the similarity
between the Gene Expression Grade and the histologic
grade. This score was determined by taking the GAD
of each sample (tumor) for the Fuzzy Molecular Grade
3-like (fMG3) class. Then, if the score was greater than
or equal 0.5 the patient is most likely to have a Grade
3-like gene expression profile (fMG3) and if the score
was less than 0.5 the patient experiences a Grade 1-like
gene expression profile (fMG1).
5. Once the optimal probe subset had been identified
for a given cohort, the histologic grade 2 and
unknown grade patients were classified into either
fMG1-like or fMG3-like according to their resulting
score (GAD).
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Gene signatures obtained were validated on an additional
cohort. In order to focus the attention to the most inform-
ative genes, custom NimbleGen Roche 4x72K gene ex-
pression microarray kit (NimbleGen Roche Diagnostics,
Meylan, France) was designed by NimbleGen support,
based on genes included in gene signatures provided by
the proposed fuzzy logic selection strategy (2030 accession
numbers). We added controls of microarray experiment
and housekeeping genes for normalization data. A mean
of 9 probes by sequence were designed.
Validation cohort
In order to validate the different generated gene signatures
(fGS), 150 frozen breast cancer tumors from the tumor
bank of the Claudius Regaud Institute (ICR Toulouse,
France) were selected. This cohort consisted of consecu-
tive invasive breast carcinoma patients treated at Claudius
Regaud Institute between 2009 and 2011. All patients in-
cluded in this cohort signed an informed consent. Clinico-
pathological characteristics of the series were similar to
those observed in routine clinical practice (i.e. majority of
pre-menopausal patients presenting with T1c, node nega-
tive, ER+ invasive ductal carcinoma of intermediate
grade). Clinical–pathological data of our samples are avail-
able in Additional file 11: Table S8. The study was ap-
proved by the local ethic committee.
RNA extraction and microarray experiments
Total RNA was extracted from 12 μm-thickcryostat sec-
tions of with Qiazol and RNeasy Lipid Tissue Kit (Qiagen,
Courtaboeuf, France). The concentration of total RNA
obtained from each tumor sample was determined using
a Nanodrop® spectrophotometer (Labtech, Palaiseau,
France) and the integrity of the RNA was assessed using a
2100 Bioanalyzer® (Agilent Technologies, Massy, France).
The percentage of tumor cells was evaluated on frozen a
section stained with hematoxylin-eosin. Double-stranded
cDNA (ds-cDNA) was synthesized from 2 μg of total
RNA using SuperScript One cycle kit (Invitrogen Life
Technologies, Saint-Aubin, France) with random primers
and Oligo(dT) primers, then cleaned with MinElute PCR
Purification Kit (Qiagen, Courtaboeuf, France). ERCC
RNA Spike-In Control Mix (Ambion Life technologies,
Saint-Aubin, France), a set of external RNA positive con-
trols, was added to total RNA at the beginning of the ex-
periment to assess accuracy of measurements of gene
expression. One μg ds-cDNA was Cy3 labeled using One-
Color DNA labeling kit (NimbleGen Roche Diagnostics,
Meylan, France). Hybridization on our Roche NimbleGen
4x72K custom microarray, washing slides and scan were
performed according to the manufacturer’s protocol
(NimbleGen Roche Diagnostics, Meylan, France). DEVA
software v1.2 (NimbleGen Roche Diagnostics, Meylan,France) was used to extract the raw intensity values. Spike
in control analyses, normalization and statistical analyses
of the data were performed with Bioconductor packages
(http://www.bioconductor.org/) and R software (version
2.14.1). All data were Robust Multichip Average (RMA)
background corrected, log2-transformed, summarized by
a robust mean for each probe. Then, housekeeping
normalization was done on the experimental data. This
method involved subtracting the average from a subset of
20 selected reference genes. As numerous studies reported
that commonly used reference genes are not constantly
expressed under different experimental conditions, we
selected the 20 most suitable reference genes among 62
candidate genes previously reported as ‘housekeeping’
genes, based on their expression stability and correl-
ation. Correlation coefficient between fluorescence and
quantity of controls were comprised from 0.96 to 1,
providing high confidence in the experimental data.
The microarray data have been deposited in the Gene
Expression Omnibus (GEO) public database. The
GSE53958 study can be found at: http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE53958.
Survival analysis
Disease-free survival was defined as the time interval
from surgery until any type of recurrence (local, re-
gional, or distant) or last date of follow-up [54]. Survival
rates were estimated by the Kaplan-meier methods and
comparison between groups were performed using Log-
rank test. Using cox proportional hazard modeling, haz-
ard ratios were estimated with their corresponding 95%
confidence interval.
All P-values reported were two-sided. For all statis-
tical tests, differences were considered significant at the
5% level. Statistical analyses were performed using R
software.
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